Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

PubWeight™: 2.73‹?› | Rank: Top 1%

🔗 View Article (PMC 2646035)

Published in Diabetes Care on November 04, 2008

Authors

Russell Scott1, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael D'Emden, Dana Tse, Marja-Riitta Taskinen, Christian Ehnholm, Anthony Keech, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators

Author Affiliations

1: Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand. fieldtrial@ctc.usyd.edu.au

Articles citing this

Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00

Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol (2013) 2.17

Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM (2009) 2.14

Dyslipidemia in obesity: mechanisms and potential targets. Nutrients (2013) 2.02

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88

Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ Cardiovasc Genet (2010) 1.77

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J (2009) 1.59

Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J (2014) 1.57

Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes (2013) 1.47

Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes (2014) 1.44

The role of triglycerides in atherosclerosis. Curr Cardiol Rep (2011) 1.38

PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol (2010) 1.34

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab (2010) 1.22

Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol (2014) 1.14

Exercise therapy in type 2 diabetes. Acta Diabetol (2009) 1.12

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol (2012) 1.10

"The metabolic syndrome... is dead": these reports are an exaggeration. Cardiovasc Diabetol (2011) 1.08

Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol (2010) 1.07

PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. Adv Nutr (2013) 1.04

Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets (2010) 1.01

Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey. BMC Public Health (2013) 0.96

Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med (2011) 0.95

Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94

Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol (2013) 0.93

Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol (2013) 0.93

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol (2010) 0.89

Management of hypertriglyceridemia in the diabetic patient. Curr Diab Rep (2010) 0.88

LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J Lipid Res (2012) 0.87

Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart Vessels (2013) 0.87

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses. Diabetes Care (2011) 0.86

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol (2016) 0.86

World congress on insulin resistance, diabetes, and cardiovascular disease: Part 1. Diabetes Care (2011) 0.85

How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? Curr Cardiol Rep (2013) 0.84

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag (2010) 0.83

Statins in cardiometabolic disease: what makes pitavastatin different? Cardiovasc Diabetol (2013) 0.83

Impact of lifestyle modification on glycemic control in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab (2013) 0.82

Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS One (2015) 0.82

The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. Indian Heart J (2013) 0.82

A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Adv Ther (2016) 0.81

Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes. Diabetes Metab J (2013) 0.81

High Human Cytomegalovirus IgG Level is Associated with Increased Incidence of Diabetic Atherosclerosis in Type 2 Diabetes Mellitus Patients. Med Sci Monit (2015) 0.81

Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. Atherosclerosis (2011) 0.81

Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD. Curr Cardiol Rev (2010) 0.81

Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther (2011) 0.81

The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol (2015) 0.80

Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud (2013) 0.80

Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study. J Clin Lipidol (2014) 0.80

Lipid lowering therapy in type 2 diabetes. Wien Med Wochenschr (2011) 0.80

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. PPAR Res (2015) 0.80

Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol (2009) 0.80

Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol (2013) 0.80

Treatment of dyslipidemia in the elderly. J Geriatr Cardiol (2011) 0.79

Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes (2014) 0.79

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovasc Diabetol (2016) 0.79

Beyond statin therapy: a review of the management of residual risk in diabetes mellitus. J R Soc Med (2010) 0.79

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. Med Sci Monit (2016) 0.79

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence. Diabetes Metab Syndr Obes (2015) 0.78

Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World J Cardiol (2016) 0.78

Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study. Pharmacogenet Genomics (2012) 0.78

Increased Rosuvastatin Dose versus Concomitant Fenofibrate and Rosuvastatin Therapy to Achieve Lipid Goal in Patients with Diabetes or Atherosclerosis with Metabolic Syndrome. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.78

Use of fibrates in the metabolic syndrome: A review. World J Diabetes (2016) 0.78

PCSK9 inhibitors - clinical applications. Aust Prescr (2016) 0.78

Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes. Diabetes Metab Syndr Obes (2009) 0.77

Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. Cardiovasc Diabetol (2015) 0.77

Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Rev Diabet Stud (2013) 0.77

Metabolic syndrome does not improve the prediction of 5-year cardiovascular disease and total mortality over standard risk markers. Prospective population based study. Medicine (Baltimore) (2014) 0.77

Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther (2012) 0.77

The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol (2015) 0.76

Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. Diabetes Care (2009) 0.76

Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med (2017) 0.75

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag (2017) 0.75

Lack of Association between High-Density Lipoprotein Cholesterol and Angiographic Coronary Lesion Severity in Chinese Patients with Low Background Low-Density Lipoprotein Cholesterol. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2015) 0.75

Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest (2017) 0.75

Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. Mol Med Rep (2015) 0.75

Treating diabetic dyslipidemia: What have we learnt from recent clinical trials? J Diabetes Investig (2010) 0.75

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag (2016) 0.75

PURLs: Add a fibrate to a statin? J Fam Pract (2010) 0.75

Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update. Wien Klin Wochenschr (2016) 0.75

Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Curr Cardiol Rep (2017) 0.75

Articles cited by this

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 118.65

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18

Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA (2007) 11.98

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk (1996) 6.18

Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation (2006) 6.17

NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 5.11

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation (1992) 4.96

Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation (1990) 3.83

Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care (2002) 2.70

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med (2002) 2.59

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med (2005) 2.22

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol (2005) 1.71

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care (2007) 1.37

Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia (2005) 1.22

Metabolic syndrome--what is the clinical usefulness? Lancet (2008) 1.20

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. Cardiovasc Diabetol (2004) 1.16

Cardiometabolic risk: a Framingham perspective. Int J Obes (Lond) (2008) 1.06

Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study. Int J Obes (Lond) (2008) 0.96

PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome. Crit Pathw Cardiol (2003) 0.85

Articles by these authors

Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52

Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med (2008) 7.47

Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31

Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20

T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis (2007) 3.96

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58

Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst (2006) 3.11

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00

Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes (2005) 2.99

Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 2.96

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90

Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet (2004) 2.86

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75

Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol (2006) 2.68

Ethical dilemma of mandated contraception in pharmaceutical research at catholic medical institutions. Am J Bioeth (2012) 2.68

Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med (2007) 2.44

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet (2011) 2.34

Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26

[ESC/EAS Guidelines for the management of dyslipidaemias]. Rev Esp Cardiol (2011) 2.21

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J (2013) 2.12

Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03

Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet (2012) 1.97

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One (2012) 1.93

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87

Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol (2012) 1.84

Evidence-based tuberculosis diagnosis. PLoS Med (2008) 1.82

Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol (2005) 1.74

An immune response network associated with blood lipid levels. PLoS Genet (2010) 1.74

Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis (2010) 1.66

Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol (2003) 1.65

Effects of a Mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects. Clin Sci (Lond) (2004) 1.63

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem (2008) 1.56

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care (2011) 1.53

Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis (2010) 1.52

Tuberculosis diagnostics trials: do they lack methodological rigor? Expert Rev Mol Diagn (2006) 1.51

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 1.51

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation (2002) 1.51

Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke (2002) 1.50

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2005) 1.50

Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol (2008) 1.49

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J (2004) 1.46

Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families. Am J Hum Genet (2002) 1.45

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis (2005) 1.44

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation (2002) 1.43

Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy. Atherosclerosis (2011) 1.42

Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis (2003) 1.39

Low HDL-C predicts the onset of transplant vasculopathy in pediatric cardiac recipients on pravastatin therapy. Pediatr Transplant (2007) 1.38

Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample. J Lipid Res (2009) 1.36

Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol Dis (2012) 1.35

Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging (2007) 1.34

PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol (2010) 1.34

Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol (2002) 1.33

Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet (2013) 1.26

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation (2003) 1.26

Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol (2008) 1.26

Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. Hum Mol Genet (2005) 1.25

Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genes. PLoS Genet (2010) 1.24

Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med (2012) 1.24

OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. J Biol Chem (2007) 1.23

New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med (2008) 1.23

Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol (2012) 1.22

Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism. Am J Hum Genet (2002) 1.22

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care (2010) 1.21

Diabetic dyslipidaemia. Curr Opin Lipidol (2006) 1.20

Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem (2007) 1.19

Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol (2009) 1.19

Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q. Am J Hum Genet (2003) 1.19

Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol (2008) 1.18

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation (2002) 1.18

Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep (2008) 1.17

Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis (2008) 1.17

APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res (2004) 1.16

USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum Mol Genet (2005) 1.16

Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer's disease. Am J Epidemiol (2008) 1.16

Common hepatic nuclear factor-4alpha variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes (2006) 1.15

Statins are diabetogenic--myth or reality? Atheroscler Suppl (2012) 1.15

Neuronal pentraxin 1: a novel mediator of hypoxic-ischemic injury in neonatal brain. J Neurosci (2004) 1.14

CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology (2013) 1.13

Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet (2011) 1.13

ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes (2009) 1.12

Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol (2013) 1.11

The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol Dial Transplant (2004) 1.11

Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation (2002) 1.11

A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res (2004) 1.11

Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res (2010) 1.10

Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J Clin Endocrinol Metab (2013) 1.07

The two variants of oxysterol binding protein-related protein-1 display different tissue expression patterns, have different intracellular localization, and are functionally distinct. Mol Biol Cell (2003) 1.07

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis (2010) 1.07

Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol (2006) 1.07

WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am J Hum Genet (2008) 1.06

Determination of human plasma phospholipid transfer protein mass and activity. Methods (2005) 1.06

Satisfaction with and perceived cultural competency of healthcare providers: the minority experience. J Natl Med Assoc (2005) 1.06

Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiol Aging (2010) 1.05

Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab (2004) 1.04

Effect of different forms of dietary hydrogenated fats on LDL particle size. Am J Clin Nutr (2003) 1.04